Who is sponsoring NCT01794455?

NCT01794455 is sponsored by Vanderbilt University.

What condition does NCT01794455 study?

NCT01794455 studies Depression, Hypertension.

What drugs are being tested in NCT01794455?

Interventions: Sertraline, Candesartan.

What is the status of NCT01794455?

NCT01794455 is currently TERMINATED.

Last reviewed 2016-08-26 · How we verify

Effects of Cerebral Hypoperfusion and Its Reversal on Late-Life Depression

NCT01794455 Phase 4 TERMINATED Results posted

This pilot proposal will test the hypothesis that altered cerebral vessel reactivity and cerebral hypoperfusion (decreased blood flow to the brain) is a core mechanism underlying the relationship between vascular disease and depression in older adults. The long-term objective of this line of research is to: A) determine the relationship between vascular reactivity, cerebral hypoperfusion and the persistence of late-life depression and B) determine if improving cerebral perfusion with angiotensin receptor blockers (ARBs) improves depression outcomes.

Details

Lead sponsor	Vanderbilt University
Phase	Phase 4
Status	TERMINATED
Enrolment	1
Start date	2013-05
Completion	2015-03

Conditions

Depression
Hypertension

Interventions

Sertraline
Candesartan

Primary outcomes

MRI Arterial Spin Labeling — Change in perfusion from baseline to week 8
MRI arterial spin labeling is a noninvasive approach to measuring cerebral blood flow. This relates to the Phase 1 sertraline arm.
Montgomery Asberg Depression Rating Scale (MADRS) — Week 8
MADRS is a measure of depression severity. This outcome applies to the sertraline Phase 1 arm.

Countries

United States